Skip to content

Hypothermic Machine Perfusion for Liver Graft Preservation

Prospective and Randomized Clinical Study of the Effect of Hypothermic Machine Perfusion on Liver Graft Preservation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07595627
Acronym
HOPE-Liver
Enrollment
40
Registered
2026-05-19
Start date
2026-05-07
Completion date
2028-05-07
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure, Liver Transplant

Keywords

Hypothermic Machine Perfusion, Liver Transplantation, Ischemia-Reperfusion Injury, Ex Vivo Liver Perfusion, Extended Criteria Donors

Brief summary

The goal of this clinical trial is to evaluate whether hypothermic machine perfusion improves liver graft preservation and post-transplant outcomes compared to conventional static cold storage in adult patients undergoing liver transplantation. This study focuses on liver grafts from deceased donors, including those with extended criteria, which are more susceptible to ischemia-reperfusion injury and early graft dysfunction. The main questions it aims to answer are: Does hypothermic machine perfusion reduce ischemia-reperfusion injury and improve early graft function after liver transplantation? Does this preservation strategy improve clinical outcomes, including graft survival, complication rates, and post-transplant recovery, compared to static cold storage? Researchers will compare hypothermic machine perfusion (ex situ, oxygenated perfusion at low temperature) to standard static cold storage to assess differences in graft preservation quality and post-transplant outcomes. Participants will: Receive a liver graft preserved either by hypothermic machine perfusion or static cold storage, according to a 1:1 randomization protocol Undergo standard liver transplantation procedures Be followed after transplantation with clinical, laboratory, imaging, and biomarker assessments at predefined time points (7 days, 30 days, 6 months, and 1 year) Additional evaluations will include biochemical markers of liver function, inflammatory and immunological mediators, mitochondrial function assessment, and histological analysis to better characterize graft injury and recovery.

Detailed description

This is a prospective, single-center, randomized controlled clinical trial designed to evaluate the impact of hypothermic machine perfusion on liver graft preservation and post-transplant outcomes in adult liver transplantation. Liver transplantation is the standard treatment for end-stage liver disease; however, outcomes are strongly influenced by graft quality. The increasing use of extended criteria donors has introduced additional challenges, as these grafts are more susceptible to ischemia-reperfusion injury, a key determinant of early graft dysfunction and post-transplant complications. Conventional static cold storage, although widely used, does not prevent ongoing anaerobic metabolism and progressive depletion of cellular energy stores, contributing to mitochondrial dysfunction, oxidative stress, and inflammatory activation upon reperfusion. Hypothermic machine perfusion has emerged as an alternative preservation strategy by providing continuous oxygenated perfusion under controlled hypothermic conditions. This approach aims to preserve mitochondrial integrity, reduce metabolic stress, and mitigate ischemia-reperfusion injury, thereby potentially improving graft viability and expanding the utilization of marginal organs. In this study, liver grafts from deceased donors will be allocated to either hypothermic machine perfusion or conventional static cold storage. Following procurement, grafts assigned to the intervention group will undergo ex situ hypothermic perfusion using an oxygenated preservation solution under controlled conditions, while the control group will follow standard institutional preservation protocols. All transplant procedures and perioperative management will be conducted according to institutional standards. Post-transplant follow-up will include clinical and laboratory monitoring to assess graft function and detect complications.

Interventions

Hypothermic machine perfusion of the liver graft is performed prior to transplantation using an ex situ perfusion system under controlled conditions, in which an oxygenated perfusate is circulated through the liver graft vasculature.

Liver graft preservation using conventional static cold storage under hypothermic conditions until transplantation.

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER
XVIVO Perfusion
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a prospective, single-center, two-arm, parallel-group randomized controlled trial comparing two liver graft preservation strategies in adult liver transplantation. Participants will be allocated in a 1:1 ratio to receive a graft preserved either by hypothermic machine perfusion or by conventional static cold storage. Randomization will be performed using a computer-generated sequence, with each participant assigned to a single intervention arm and no crossover between groups. The intervention is applied at the graft level prior to transplantation. All transplant procedures and perioperative management will be conducted according to standard institutional protocols.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Donor-related inclusion criteria: * Liver donors with confirmed diagnosis of brain death. * Extended criteria donors (ECD). * Age ≥18 years. * Family consent for organ donation obtained. * Negative serology for HTLV, HIV, Chagas disease, and hepatitis B and C. Recipient-related inclusion criteria: * Adult patients (≥18 years) undergoing liver transplantation. * Diagnosis of end-stage liver disease or indication for liver transplantation. * Candidates for primary liver transplantation. * Ability to understand and provide written informed consen Donor-related

Exclusion criteria

* Presence of moderate or severe hepatic steatosis. * Pediatric donors. * Donors classified as ideal, defined by the simultaneous presence of all of the following criteria: Age \<35 years, Body mass index (BMI) \<28 kg/m², No history of cardiopulmonary resuscitation, Norepinephrine requirement \<0.5 µg/kg/min, Liver enzymes (AST or ALT) ≥2 times the upper limit of normal, Intensive care unit stay ≤7 days Recipient-related

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Early Allograft Dysfunction (EAD)Within 7 days after transplantationEarly allograft dysfunction is defined according to established clinical criteria, including at least one of the following within the first 7 days after transplantation: total bilirubin ≥10 mg/dL on day 7, international normalized ratio (INR) ≥1.6 on day 7, or alanine or aspartate aminotransferase (ALT or AST) levels \>2000 IU/L within the first 7 days.

Secondary

MeasureTime frameDescription
Change in Liver Function Tests (AST, ALT, Total Bilirubin)At 7 days, 30 days, 6 months, and 1 year after transplantationSerial measurements of liver function parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin, obtained through routine laboratory testing following liver transplantation. Values will be analyzed over time to assess graft function and recovery.
Incidence of Acute Kidney Injury (AKI)Within 7 days and up to 30 days after transplantationOccurrence of acute kidney injury following liver transplantation, defined based on changes in serum creatinine levels according to established clinical criteria.
Incidence of Post-Reperfusion Syndrome (PRS)During transplantation procedureOccurrence of post-reperfusion syndrome during liver transplantation, defined as a decrease in mean arterial pressure greater than 30% from baseline within the first minutes after graft reperfusion, with or without the need for increased vasopressor support.
Incidence of Post-Transplant ComplicationsUp to 1 year after transplantationOccurrence of post-transplant complications, including biliary complications, vascular complications, infections, and acute rejection, assessed according to standard clinical definitions and severity grading systems.
Graft SurvivalUp to 1 year after transplantationSurvival of the transplanted liver graft without the need for retransplantation
Patient SurvivalUp to 1 year after transplantationSurvival of the transplant recipient following liver transplantation.
Length of Intensive Care Unit StayFrom liver transplantation until intensive care unit discharge, up to 30 daysDuration of stay in the intensive care unit following liver transplantation.
Length of Hospital StayFrom liver transplantation until hospital discharge, up to 30 daysDuration of hospital stay following liver transplantation.

Countries

Brazil

Contacts

CONTACTWellington Andraus, MD, PhD
wellington@usp.br+5511982118909
CONTACTAlexandre Santana, PhD
alesantana@usp.br+5511931002779
PRINCIPAL_INVESTIGATORWellington Andraus, MD, PhD

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)

STUDY_CHAIRRubens Macedo Junior, MD, PhD

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)

STUDY_DIRECTORAlexandre Santana, PhD

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026